Peter Beetham is recorded as Board Member at Cibus, Inc. (CBUS) since May 31, 2023 and CEO and COO at Cibus, Inc. (CBUS). The newest filing on record that lists Peter Beetham as CEO at Cibus, Inc. (CBUS) is dated April 20, 2026. The newest filing on record that lists Peter Beetham as COO at Cibus, Inc. (CBUS) is dated April 19, 2024. Cibus, Inc. reported in an 8-K filed June 9, 2026 that Peter Beetham resigned as director, effective June 8, 2026. Cibus, Inc. reported in an 8-K filed February 28, 2025 that Peter Beetham was appointed Interim Chief Executive Officer, effective February 24, 2025. Cibus, Inc. reported in an 8-K filed June 1, 2023 that Peter Beetham was appointed President and Chief Operating Officer, effective May 31, 2023. Equibles holds 4 filed executive changes naming Peter Beetham; each is listed under recent activity with its source filing. The proxy statement of Cibus, Inc. reports total compensation of $1,364,345 for Peter Beetham in fiscal 2025, including a base salary of $630,579. Disclosed compensation is on record for 3 fiscal years. Peter Beetham has spoken on 12 earnings calls across 1 company, most recently for Cibus, Inc. on August 13, 2026. Cibus, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Cibus, Inc. includes Craig Wichner (CEO and Board Member), Michael Carr (CEO), Rory Riggs (Chairman and Board Member) and 7 others.
“Dr. Beetham resigned from the Board also effective June 8, 2026.”
“Pursuant to the Company's succession planning strategy, Peter Beetham, the Company's President and Chief Operating Officer, was appointed as Interim Chief Executive Officer while the Company's Board of Directors initiates a search for the Company's next Chief Executive Officer.”
Cibus, Inc. Form 8-K, filed February 28, 2025
· Read the filing
Peter Beetham on recent calls
“It is great to have Craig step in to lead Cebus as our new CEO. We are really fortunate here to have a farming industry leader, a scientist and a financier to lead SEBIS to the next level.”
“I'm so pleased to report continued momentum toward our commercial goals across our priority programs during the first quarter of 2026. If I had to distill our message today into a single word, it would be execution.”
“By any measure, 2025 was a landmark year for CBIS. Not because of any single headline, but because of a convergence of key themes that are shaping the trajectory of the gene editing industry.”
“This past quarter has further focused our commercialization and production activities. I clearly see our company as a coiled spring, ready to deliver gene editor traits for years to come.”
